Notice: This company has been marked as potentially delisted and may not be actively trading. Pardes Biosciences (PRDS) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Pardes Hanna, Israel - Weather Forecasts | Maps | News - Yahoo WeatherOctober 31, 2023 | yahoo.comPardes Biosciences Announces Closing of Tender OfferAugust 31, 2023 | finance.yahoo.comTrading was temporarily halted for "PRDS" at 07:08 PM with a stated reason of "News pending."August 31, 2023 | marketbeat.comMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesAugust 28, 2023 | finance.yahoo.comMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesAugust 17, 2023 | finance.yahoo.comPardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28August 3, 2023 | msn.comPardes Biosciences Shares Rise 15% After Buyout Offer From MediPacificJuly 19, 2023 | marketwatch.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)July 19, 2023 | markets.businessinsider.comJMP Securities Downgrades Pardes Biosciences (PRDS)July 18, 2023 | msn.comPRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to ShareholdersJuly 17, 2023 | benzinga.comPardes Biosciences stock rallies on buyout offer from MediPacificJuly 17, 2023 | msn.comWhy Pardes Biosciences Shares Are Rising MondayJuly 17, 2023 | benzinga.comPardes Biosciences To Be Acquired By MediPacific; Pardes Up In Pre-marketJuly 17, 2023 | markets.businessinsider.comPardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsJuly 17, 2023 | finance.yahoo.comTrading was temporarily halted for "PRDS" at 06:07 AM with a stated reason of "News pending."July 17, 2023 | marketbeat.comAll You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to BuyJune 5, 2023 | finance.yahoo.comPardes Biosciences Seeking Strategic AlternativesMay 17, 2023 | seekingalpha.comPardes Biosciences (PRDS) Receives a Hold from SVB SecuritiesMay 9, 2023 | markets.businessinsider.comPardes Biosciences Inc.May 6, 2023 | barrons.comPardes Biosciences, Inc: Pardes Biosciences Reports First Quarter 2023 Financial ResultsMay 6, 2023 | finanznachrichten.deRecap: Pardes Biosciences Q1 EarningsMay 5, 2023 | msn.comPardes Biosciences Reports First Quarter 2023 Financial ResultsMay 5, 2023 | finance.yahoo.comAnalyst Rating: Will Pardes Biosciences Inc (PRDS) Stock Do Better Than the Market?April 12, 2023 | benzinga.comPardes Biosciences cut at Jefferies on COVID drug failureApril 7, 2023 | seekingalpha.comSVB Leerink Downgrades FS Development Corp II (PRDS)April 4, 2023 | msn.comSVB Securities downgrades Pardes Biosciences (PRDS) to a HoldApril 4, 2023 | markets.businessinsider.comPardes slumps ~10% after COVID drug trial failure prompts strategic reviewApril 3, 2023 | msn.comPardes Biosciences Looks For Alternatives After Failed COVID-19 StudyApril 3, 2023 | msn.comWill Pardes Biosciences (NASDAQ:PRDS) Spend Its Cash Wisely?April 3, 2023 | finance.yahoo.comPardes Biosciences to suspend COVID-19 drug development after mid-stage trial failsApril 3, 2023 | reuters.comPardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19April 3, 2023 | finance.yahoo.comTrading was temporarily halted for "PRDS" at 07:04 AM with a stated reason of "News pending."April 3, 2023 | marketbeat.comSVB Securities Reaffirms Their Buy Rating on Pardes Biosciences (PRDS)March 20, 2023 | markets.businessinsider.comPardes Biosciences Stock (NASDAQ:PRDS), Guidance and ForecastMarch 16, 2023 | benzinga.comPardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 14, 2023 | finance.yahoo.comPardes Biosciences to Present at SVB Securities Global Biopharma ConferenceFebruary 1, 2023 | finance.yahoo.comRM LAW Announces Investigation of Pardes Biosciences, Inc.January 30, 2023 | prnewswire.comIeq Capital LLC Invests $105,000 in Pardes Biosciences, Inc. (NASDAQ:PRDS)Ieq Capital LLC purchased a new position in shares of Pardes Biosciences, Inc. (NASDAQ:PRDS - Get Rating) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 56,672 shares of the company's stock, valued at approximately $105,00January 30, 2023 | marketbeat.comPardes Biosciences, Inc. to Post FY2026 Earnings of $4.35 Per Share, SVB Leerink Forecasts (NASDAQ:PRDS)Pardes Biosciences, Inc. (NASDAQ:PRDS - Get Rating) - Equities research analysts at SVB Leerink issued their FY2026 EPS estimates for shares of Pardes Biosciences in a note issued to investors on Friday, January 27th. SVB Leerink analyst R. Ruiz forecasts that the company will post earnings of $4January 30, 2023 | marketbeat.comPardes Biosciences (NASDAQ:PRDS) PT Lowered to $9.00SVB Leerink dropped their target price on Pardes Biosciences from $12.00 to $9.00 and set an "outperform" rating on the stock in a research report on Friday.January 27, 2023 | marketbeat.comPRDS Pardes Biosciences, Inc.January 25, 2023 | seekingalpha.com(SPAC) Special Purpose Acquisition Investigation: KIND, OPFI, OTMO, PRDS, Contact Shareholder Rights Law Firm Johnson FistelJanuary 14, 2023 | benzinga.comPardes Biosciences, Inc. (NASDAQ:PRDS) Is Expected To Breakeven In The Near FutureNovember 13, 2022 | finance.yahoo.comPardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 8, 2022 | apnews.comPardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 8, 2022 | finance.yahoo.comPardes Biosciences to Present at Jefferies London Healthcare ConferenceNovember 1, 2022 | finance.yahoo.comHere's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn SituationSeptember 28, 2022 | finance.yahoo.comPardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of DirectorsSeptember 14, 2022 | finance.yahoo.comPardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12, 2022 | finance.yahoo.comPardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12, 2022 | finance.yahoo.com Get Pardes Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PRDS and its competitors with MarketBeat's FREE daily newsletter. Email Address What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today. PRDS Media Mentions By Week PRDS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRDS News Sentiment▼0.000.48▲Average Medical News Sentiment PRDS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRDS Articles This Week▼00▲PRDS Articles Average Week Get Pardes Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PRDS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LianBio News PHAXIAM Therapeutics News Alpha Tau Medical News BriaCell Therapeutics News eFFECTOR Therapeutics News Fortress Biotech News GeoVax Labs News Innovid News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRDS) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pardes Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pardes Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRDS Stock Alerts